Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance

MYRIAD GENETICS INC

2025-Q1 EPS reported $0.00 revenue$195,900,000

GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.
Prenatal revenue grew 11% YoY; Pharmacogenomics revenue fell 20% due to UnitedHealthcare coverage cut for GeneSight.
Gross margin 69% (+40 bps YoY) on lab efficiencies; operating loss $29M vs $27.9M YoY.
Updated FY2025 revenue guidance lowered to $807-823M from $840-860M; adjusted EPS now $(0.02)-$0.02.
CEO cited challenges in GeneSight and unaffected hereditary cancer; taking steps to reduce costs and drive growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.